# A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients

> **NCT04116411** · PHASE2 · ACTIVE_NOT_RECRUITING · sponsor: **Cecilia Soderberg-Naucler** · enrollment: 220 (estimated)

## Conditions studied

- Glioblastoma Multiforme

## Interventions

- **DRUG:** Valganciclovir Tablets
- **DRUG:** Temozolomide 120 mg
- **RADIATION:** Radiotherapy 60 Gy
- **DRUG:** Placebo oral tablet

## Key facts

- **NCT ID:** NCT04116411
- **Lead sponsor:** Cecilia Soderberg-Naucler
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2019-09-04
- **Primary completion:** 2027-09-16
- **Final completion:** 2027-09-16
- **Target enrollment:** 220 (ESTIMATED)
- **Last updated:** 2025-12-22

## Collaborators

- [object Object]
- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT04116411

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT04116411, "A Clinical Trial Evaluating the Efficacy of Valganciclovir in Glioblastoma Patients". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT04116411. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*